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Background: Health authorities in numerous countries recommend periconceptional folic acid to pregnant women
to prevent neural tube defects. The objective of this study was to examine the association of folic acid
supplementation during different periods of pregnancy and of dietary folate intake with the risk of spontaneous
preterm delivery (PTD).
Methods: The Norwegian Mother and Child Cohort Study is a population-based prospective cohort study. A total
of 65,668 women with singleton pregnancies resulting in live births in 1999–2009 were included. Folic acid
supplementation was self-reported from 26 weeks before pregnancy until week 24 during pregnancy. At gestational
week 22, the women completed a food frequency questionnaire, which allowed the calculation of their average
total folate intake from foods and supplements for the first 4–5 months of pregnancy. Spontaneous PTD was
defined as the spontaneous onset of delivery between weeks 22+0 and 36+6 (n = 1,628).
Results: The median total folate intake was 266 μg/d (interquartile range IQR 154–543) in the overall population
and 540 μg/d (IQR 369–651) in the supplement users. Eighty-three percent reported any folic acid supplementation
from <8 weeks before to 24 weeks after conception while 42% initiated folic acid supplementation before their
pregnancy. Cox regression analysis showed that the amount of folate intake from the diet (hazard ratio HR 1.16;
confidence interval CI 0.65-2.08) and from the folic acid supplements (HR 1.04; CI 0.95-1.13) was not significantly
associated with the risk of PTD. The initiation of folic acid supplementation more than 8 weeks before conception
was associated with an increased risk for PTD (HR 1.19; CI 1.05-1.34) compared to no folic acid supplementation
pre-conception. There was no significant association with PTD when supplementation was initiated within 8 weeks
pre-conception (HR 1.01; CI 0.88-1.16). All analyses were adjusted for maternal characteristics and socioeconomic,
health and dietary variables.
Conclusions: Our findings do not support a protective effect of dietary folate intake or folic acid supplementation
on spontaneous PTD. Pre-conceptional folic acid supplementation starting more than 8 weeks before conception
was associated with an increased risk of PTD. These results require further investigation before discussing an
expansion of folic acid supplementation guidelines.
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Folate is a B-vitamin essential for one-carbon metabolism
and takes part in amino acid metabolism as well as DNA
synthesis, repair and methylation [1,2]. Women are espe-
cially susceptible to folate deficiency during pregnancy,
which is a period of rapid fetal growth, organ differentiation
and high rates of cell division [1,3,4]. Since the 1950s, folic
acid supplementation has been known to prevent megalo-
blastic anemia during pregnancy [5]. In the 1990s, large
randomized trials demonstrated that peri-conceptional
folic acid supplementation can prevent neural tube de-
fects (NTD) in the newborn infant [6-8]. Today, na-
tional health authorities in many countries recommend
periconceptional folic acid supplementation, and some
countries have introduced mandatory folate fortifica-
tion of foods [1,3,4,9,10]. In Norway, folic acid supple-
mentation of 400 μg/d is recommended from the time
of planning a pregnancy to gestational week 12 [2,11],
as is a daily folate intake of 500 μg/d. This is in line
with the Nordic Nutrition Recommendations [2].
Maternal folate status has also been associated with
other adverse pregnancy outcomes such as preeclampsia,
malformations such as orofacial clefts, spontaneous
abortion, fetal death, fetal growth restriction and pre-
term delivery (PTD), although these results still remain
inconclusive [1].
PTD, defined by the World Health Organization (WHO)
as birth occurring before 37 weeks of gestation, is consid-
ered a major global health problem and is strongly associ-
ated with neonatal mortality as well as short- and long-term
morbidity [12-14]. Spontaneous PTD is a common, complex
condition with a prevalence of approximately 7% in the
Norwegian population [15]. However, the effect of any single
environmental factor is difficult to measure without large-
scale studies [15]. Modern obstetrics are still not able to pre-
dict, prevent or treat PTD [16]. Progesterone substitution,
the only promising intervention identified to date, has been
shown to reduce the chance of spontaneous PTD in high-
risk pregnancies, but such cases account for only a small
proportion of all pregnancies [17-19].
In the past decade, some observational studies have
found that folic acid supplementation reduces the risk
of PTD [20-22]. In some studies, this effect has been
documented with an extended folic acid supplementa-
tion scheme or dosage compared with schemes based
on NTD prevention, e.g., pre-conceptional folic acid
supplementation for one year or longer [21] or third-
trimester folic acid supplementation [22]. The most re-
cent Cochrane review, based on data from 21 studies
including one of the largest randomized controlled tri-
als (RCT), as well as a recent meta-analysis of all RCTs
published to date, could not confirm any effect of the
maternal folate status on the gestational length or the
risk of spontaneous PTD [23,24]. The comparabilityand generalizability of these earlier studies, which focused
on the association of folate status and folic acid supplemen-
tation with pregnancy outcome, is limited because folic acid
supplementation was assessed without considering other
folate sources, the study populations had different levels of
dietary folate intake, inadequate sample sizes, limited ad-
justment for important confounders, and/or retrospective
study designs with folate data collection only after delivery
[1,4]. Although PTD is a heterogeneous pregnancy out-
come with different etiologies (early vs. late or iatrogenic vs.
spontaneous), previous studies have mostly treated PTD as
one entity, obscuring the differences in risk among PTD
subtypes [25].
The Norwegian Mother and Child Cohort Study (MoBa)
can meet a number of these challenges in study design, a
requirement for addressing the inconsistencies in the field.
MoBa includes 106,707 pregnancies, enabling the investi-
gation of common complex pregnancy outcomes such as
PTD. A detailed prospective assessment of folic acid sup-
plementation starting from 6 months before conception
throughout the pregnancy period, data regarding dietary
folate intake and comprehensive information about life-
style habits, health and socioeconomic status provide a
unique opportunity to study the association between fol-
ate intake and PTD. For example, the effect of folic acid
supplementation can be compared between women with
low and high dietary folate intakes. By taking into account
the amount of dietary folate and folic acid supplementa-
tion during different periods of pregnancy, it might be
possible to define the folic acid supplementation scheme
most likely to affect PTD.
The aim of this study was to examine the association
of maternal folate intake from both supplemental and
dietary sources with the risk of spontaneous PTD, with
sub-analyses of early and late spontaneous PTD. The as-
sociation of folic acid supplementation with PTD was
studied in a stratified sample of women with low and
high dietary folate intakes (</≥170 μg/d).
Methods
Study population
The dataset is part of the MoBa cohort, initiated by and
maintained at the Norwegian Institute of Public Health
[15]. In brief, MoBa is a nation-wide pregnancy cohort
that has included more than 106,000 pregnancies in the
years from 1999 to 2009. The women were recruited
through a postal invitation in connection with a routine
ultrasound examination offered to all pregnant women
in Norway approximately 17 weeks of gestation. Overall,
38.5% of the invited women participated. They were
asked to fill in questionnaires focused on overall health
status, lifestyle behavior and diet at gestational weeks
15–17 (Q1) and 30 (Q3). At week 22, they completed a
food frequency questionnaire (FFQ). All questionnaires
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stitute of Public Health [26]. The present study used
data from version 5 of the quality-assured data files
made available for research in 2010. The MoBa database
is linked to pregnancy and birth records from the Med-
ical Birth Registry of Norway (MBRN) [27]. Informed
written consent was obtained from each participant.
The Regional Committee for Medical Research and the
Norwegian Data Inspectorate approved the study.
Of 106,707 pregnancies included in the MoBa version
5, 103,921 pregnancies resulted in live-born singletons.
Complete data for all 3 questionnaires including infor-
mation about folate intake were available for 89,032
pregnancies. Women reporting improbable energy intakes
of <4.5 MJ or >20 MJ were excluded [28], leaving 87,565
pregnancies. After exclusion of women with diabetes
mellitus, hypertension, autoimmune diseases, inflammatory
bowel diseases, systemic lupus erythematosus, rheumatoid
arthritis, scleroderma, other immune-compromised condi-
tions and those that underwent in-vitro fertilization, as
well as those with pregnancy-related complications such
as preeclampsia, hypertension, gestational diabetes, pla-
cental abruption, placenta previa, cervical cerclage and
serious fetal malformations, 75,916 pregnancies were in-
cluded in the study. Pregnancies with a gestational length
of <22+0 or >42+6 weeks were excluded from further ana-
lysis, leaving 75,718 remaining. If a woman participated
for more than one pregnancy, only her first pregnancy
enrolled was included, leaving 65,668 pregnancies for
analyses.
Outcome
The gestational age in days was determined with a second-
trimester ultrasound in 98.3% of the pregnancies and was
based on the last menstrual period in the remaining cases.
Spontaneous PTD was defined as birth after preterm labor
or pre-labor rupture of the membranes between 22+0 and
36+6 weeks. Spontaneous PTD subgroups for early (22+0-
33+6) and late (34+0-36+6) PTD were analyzed.
Exposure
Amount of folate intake
The amount of folate intake was calculated from the
MoBa FFQ, a semi-quantitative questionnaire designed to
yield information regarding the dietary habits and intake
of dietary supplements during the first 5 months of preg-
nancy. The questionnaires were read optically, and the nu-
trient and energy intakes were calculated using FoodCalc
[29] and the Norwegian Food Composition Table [30]. For
the calculation of nutrients in the dietary supplements, an
Access database (Microsoft Office 2003) containing the
nutrient values of more than 1,000 dietary supplements
was created and continuously updated. Dietary supple-
ments commonly sold in Norway were registered basedon information provided by the respective manufacturer,
whereas nutritional information concerning dietary supple-
ments bought from the Internet or abroad were obtained
from the manufacturer’s or supplier’s homepage. A data
program connected to the Access database read all food
supplements recorded by the MoBa participants. The
process of extracting dietary and supplement data is de-
scribed in detail elsewhere [31,32].
Dietary folate was defined as 60% of the reported fol-
ate intake from foods, as only approximately 60% may
be biologically accessible in comparison to that from the
synthetic folic acid in supplements [1,3]. The total folate
intake was thus calculated as supplemental folic acid +
0.6 × folate intake from foods.
The daily folate intake was also categorized into 4
groups: <170 μg/d (corresponding to the earlier WHO rec-
ommendation for all women to prevent anemia [10,33]),
170–500 μg/d (corresponding to the current Nordic Nutri-
tion Recommendations for pregnant women for the pre-
vention of NTDs [2]), 500–1000 μg/d (corresponding to
the tolerable upper limit for folic acid [2]) and >1000 μg/d.
Time of folic acid supplementation
The women reported their folic acid supplement use
from 26 weeks before conception until gestational week
24 in 4-week intervals, including the period and fre-
quency of supplementation. A woman was defined as a
folic acid supplement user if she reported folic acid sup-
plementation more than once a week in a registered
4-week period. Folic acid could be consumed either in
the form of a folic acid supplement or as part of multivi-
tamins. The most commonly used folic acid supplements
for pregnant women in Norway contain 400 μg of folic
acid, while the most commonly used multivitamin sup-
plements contain 200 μg of folic acid. For this study, the
start of folic acid supplementation was categorized as
start during 26–9 weeks before conception, start during
8–0 weeks before conception, and no pre-conceptional
folic acid supplementation.
Covariates
Information regarding the maternal age at delivery as well
as the child’s sex is available from the MBRN. Parity was
based on data from both the MoBa and MBRN and cate-
gorized according to the number of previous pregnancies
of ≥22+0 weeks’ duration. Marital status was defined as ei-
ther married/cohabitant or not. The self-reported pre-
pregnancy heights and weights were used to calculate the
pre-pregnancy body mass index (BMI) and were grouped
according to the WHO classification as underweight
(<18.5 kg/m2), normal (18.5-24.9 kg/m2), overweight
(25.0-29.9 kg/m2) and obese (≥30.0 kg/m2). Maternal edu-
cation was categorized as ≤12 y, 13–16 y and ≥17 y. The
history of previous PTD at 22+0-36+6 weeks of gestation,
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in the MBRN, were taken into account as dichotomous var-
iables. Women reported smoking habits during pregnancy
in Q1 and were categorized as non-smokers, occasional or
daily smokers. The alcohol intake from different sources
was self-reported in the FFQ (glasses/d, week or month)
and calculated as g/d. The household income was classified
as both the participant and her partner having <300,000
Norwegian Kroner (NOK)/y, as either the participant or
her partner having ≥300,000 NOK/y or as the participant
and her partner both having ≥300,000 NOK/y. Vitamin A
supplementation was registered and categorized in the
same manner as described for folic acid. These variables
were used as a proxy for multivitamin supplementation, as
there are no products on the Norwegian market containing
vitamin A alone, and vitamin A is part of all common
multivitamin preparations. In MoBa more than 99% of the
participants are of Caucasian ethnicity; hence, ethnicity was
not a relevant confounder.
Statistical methods
All statistical analyses were performed using IBM SPSS
Statistics 19.0 and R 2.13.1 software. Total dietary folate in-
take from foods and supplements (median (IQR)) in rela-
tion to the maternal characteristics was studied with the
Kruskal-Wallis test. The start of folic acid supplementation
in relation to the maternal characteristics was studied with
Pearson's chi-squared test. The association of total dietary
folate intake and spontaneous PTD was estimated as a haz-
ard ratio (HR) with a 95% confidence interval (CI) by using
Cox regression both in an unadjusted model and adjusted
for the above-mentioned covariates. In these models, the
event was defined as a spontaneous PTD; all iatrogenic de-
liveries and deliveries after the preterm (≥37+0 weeks) or
early preterm (≥34+0 weeks) period were censored. The
proportional hazards assumption was investigated by test-
ing and inspecting scaled Schoenfeld residuals using R
function cox.zph [34]. Statistical significance was assumed
for 2-sided p-values of <0.05.
Results
Folate intake and folic acid supplementation in the study
population
The median total dietary folate intake during the first
five months of pregnancy and start of folic acid supple-
mentation according to maternal characteristics are
presented in Table 1. Dietary folate intake was higher in
women who were older, did not smoke, had normal
BMI (18.5-24.9 kg/m2), who were having their first
child, were married/cohabitant, who had higher educa-
tion levels and family incomes. Women having experi-
enced PTD, as well as women with a history of spontaneous
abortion, had significantly lower total folate intakes. While
women with a history of spontaneous abortion had moreoften started folic acid supplementation early, no compar-
able pattern in women with a history of PTD was found
(Table 1).
Figure 1 illustrates the pattern of folic acid supplemen-
tation in the study population compared to vitamin A
supplementation (as a proxy for multivitamin consump-
tion) over the course of pregnancy. 83% of all women in
the study reported folic acid supplementation at some
point before and/or during pregnancy (Figure 1). While
42% began folic acid supplementation prior to concep-
tion, nearly 75% used supplements containing folic acid
in the first trimester with decreasing use towards the
end of pregnancy. At the same time, vitamin A supple-
mentation was much more stable over the whole length
of the pregnancy. The folic acid content of the reported
supplements varied considerably, with only 2 women
consuming folic acid amounts of >5000 μg/d, 575 con-
suming >1000 μg/d (1%), 6,160 consuming >500 μg/d
(9%), 9,589 consuming >400 μg/d (15%), 24,337 consum-
ing >200 μg/d (37%) and 30,708 consuming >100 μg/d
(47%). Among supplement users, the median daily folic
acid supplementation was 400 μg/d (interquartile range
IQR 200–429). As presented in Table 2, folic acid from
supplements was the main folate source in supplement
users, while the main source was dietary folate in the
whole population. There is no mandatory folate fortifica-
tion of foods in Norway, and only 0.4% (n = 272) of the
study population reached the Nordic Nutrition Recom-
mendation of 500 μg/d with their dietary folate intake
(2.8%, n = 1,854, if the dietary folate was not adjusted for
bio-availability). Of the study participants, 31%, n = 20,369,
achieved the recommended levels with their total folate
intake (39.6%, n = 26,015, if the dietary folate was not ad-
justed for bio-availability).
Folate intake from different sources and risk for
spontaneous PTD
The median gestational age in this study population was
282 days (IQR 245–288), with 2,236 cases of PTD and
1,628 cases of spontaneous PTD. Of these, 264 babies were
delivered before 34+0 weeks of gestation. Thus the PTD
rate in our study population is 3.4%, approximately half of
the PTD rate in the general Norwegian population as we
excluded all risk-pregnancies due to maternal disease,
pregnancy-complications or fetal malformation.
There was no significant association between the amount
of folate intake from the diet or supplements and the risk
of spontaneous PTD (Table 3). Likewise, no association
was found when the total folate intake was categorized
according to the former WHO recommendation for
women (>170 μg/d), the current Nordic Nutrition Recom-
mendations for pregnant women (>500 μg/d) and the tol-
erable upper limit for folic acid supplementation (<1000
μg/d) (Additional file 1: Table S1). Cox regression for the
Table 1 Folate variables and maternal characteristics
Total folate intake (μg/d) Initiation of preconceptional folic acid supplementation, n (%)
n (%) median (IQR) p1 >8 w 0-8 w no p2
Total 65668 (100) 266 (153–543) 15471 (24) 12308 (19) 37889 (58)
<25 7583 (12) 228 (143–504) 842 (11) 879 (12) 5862 (77)
Maternal age 25-29 22745 (35) 275 (154–547) <0.0001 4990 (22) 4605 (20) 13150 (58) <0.0001
in years 30-34 27782 (42) 270 (155–546) 7475 (27) 5662 (20) 14645 (53)
>34 7558 (12) 276 (160–547) 2164 (29) 1162 (15) 4232 (56)
Pre- <18.5 2004 (3) 294 (160–554) 439 (22) 344 (17) 1221 (61)
pregnancy 18.5-24.9 43198 (66) 278 (157–549) <0.0001 10611 (25) 8388 (19) 24199 (56) <0.0001
BMI in 25-30 13448 (21) 248 (148–533) 2999 (22) 2483 (18) 7966 (59)
kg/m2 ≥30 5341 (8) 229 (141–515) 1146 (21) 822 (15) 3373 (63)
missing 1677 (3) 226 (144–491) 276 (16) 271 (16) 1130 (67)
0 33501 (51) 320 (165–566) 8753 (26) 6031 (18) 18717 (56)
1 20743 (32) 233 (146–526) <0.0001 4581 (22) 4466 (22) 11696 (56) <0.0001
Parity 2 9199 (14) 211 (144–480) 1752 (19) 1525 (17) 5922 (64)
3+ 2140 (3) 200 (140–388) 370 (17) 272 (13) 1498 (70)
missing 85 (0,1) 183 (121–401) 15 (18) 14 (16) 56 (66)
Marital yes 63134 (96) 268 (154–544) <0.0001 15184 (24) 12101 (19) 35849 (57) <0.0001
status no 2534 (4) 232 (147–493) 287 (11) 207 (8) 2040 (81)
Maternal <13 20618 (31) 214 (138–483) 3237 (16) 2774 (13) 14607 (71)
education 13 - 16 27249 (41) 291 (157–553) <0.0001 6841 (25) 5601 (21) 14807 (54) <0.0001
in >16 16415 (25) 331 (171–569) 5096 (31) 3718 (23) 7601 (46)
years missing 1386 (2) 243 (144–528) 297 (21) 215 (16) 874 (63)
History of no 63433 (97) 267 (154–543) <0.0001 14980 (24) 11879 (19) 36574 (58) 0.18
preterm yes 2155 (3) 237 (151–521) 472 (22) 411 (19) 1272 (59)
delivery missing 80 (0,1) 252 (144–554) 19 (24) 18 (23) 43 (54)
History of no 53123 (81) 269 (154–544) <0.0001 11655 (22) 10112 (19) 31356 (59) <0.0001
abortion yes 12545 (19) 251 (150–540) 3816 (30) 2196 (18) 6533 (52)
never 59678 (91) 277 (156–548) 14752 (25) 11691 (20) 33235 (56)
Smoking occasionally 1879 (3) 218 (141–453) <0.0001 255 (14) 231 (12) 1393 (74) <0.0001
habits daily 3733 (6) 190 (128–390) 399 (11) 319 (9) 3015 (81)
missing 378 (1) 221 (140–451) 65 (17) 67 (18) 246 (65)
Alcohol no alcohol 55368 (84) 289 (159–551) 13360 (24) 10672 (19) 31336 (57)
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Table 1 Folate variables and maternal characteristics (Continued)
consumption <0.5 6565 (10) 245 (150–528) <0.0001 1403 (21) 1162 (18) 4000 (61) <0.0001
in units/week ≥0.5 3735 (6) 149 (117–209) 708 (19) 474 (13) 2553 (68)
Partners with 0 19439 (30) 225 (143–507) <0.0001 3246 (17) 2853 (15) 13340 (69)
income of 1 26938 (41) 265 (154–542) 6287 (23) 5253 (20) 15398 (57) <0.0001
>300,000 2 17472 (27) 337 (169–572) 5687 (33) 3939 (23) 7846 (45)
NOK/year missing 1819 (3) 227 (147–511) 251 (14) 263 (14) 1305 (72)
Baby's male 33445 (51) 262 (152–541) 0.003 7875 (24) 6198 (19) 19372 (58) 0.3
sex female 32223 (49) 270 (155–545) 7596 (24) 6110 (19) 18517 (57)
Tertiles of 1 21890 (33) 179 (115–503) 5251 (24) 4031 (18) 12608 (58)
energy intake 2 21890 (33) 263 (155–548) <0.0001 5397 (25) 4307 (20) 12186 (56) <0.0001
in MJ 3 21888 (33) 325 (203–591) 4823 (22) 3970 (18) 13095 (60)
Amount of total daily folate intake (FFQ data) and initiation of folic acid supplementation (Q1 data) according to maternal characteristics, from 65,668 participants in the Norwegian Mother and Child Cohort Study
(2002 – 2009).
1 p-value, estimated with Kruskal-Wallis test.
2 p-value, estimated with Pearson's chi-squared test.
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http://www.biomedcentral.com/1471-2393/13/160sub-groups of early and late spontaneous PTD did not re-
veal any significant associations between the folate intake
and pregnancy outcome (not shown). Testing the propor-
tional hazards assumptions revealed a slight misfit for the
parity variable. Therefore all analyses were also run with
stratified Cox regression using parity as strata. The changes
from the unstratified analyses were however marginal and
did not change any pattern or conclusion.
Initiation of folic acid supplementation and risk for
spontaneous PTD
The initiation of folic acid supplementation more than 8
weeks before conception was associated with a marginally
increased risk of spontaneous PTD also after adjusting for
potential confounders (Table 4 and Additional file 2: Figure
S1a; HR 1.19; confidence interval CI 1.05-1.34). The initi-
ation of supplementation more than 8 weeks before concep-
tion was significantly associated with early (<34+0 weeks)
but not late spontaneous PTD (Additional file 3: Figure S1b)
however the difference in HR was not significant. After
stratification for the total dietary folate intake from foods,
the initiation of folic acid supplementation more than 8
weeks before conception was significantly associated with an
increased risk of spontaneous PTD for those women with
low dietary folate intakes (HR 1.22; CI 1.04-1.45). The inter-
action between dietary folate intake and initiation of supple-
mentation was not significant, though. The same association
was found in the subgroup of early but not late spontaneous
PTD (Additional file 4: Table S2).
A history of earlier adverse pregnancy outcomes could
be a motive for the early initiation of folic acid supplemen-
tation in subsequent pregnancies. However, the analysis ofFigure 1 Prevalence of folic acid and vitamin A supplementation duri
supplementation during pregnancy (Q1 and Q3 data) in women with spon
65,668 participants in the Norwegian Mother and Child Cohort Study (2002the subgroup of primi-gravidae (n = 23,919, 36%) showed
the same overall results, with even larger HRs for the early
initiation of folic acid supplementation (HR 1.32; CI 1.11-
1.57).
The early initiation of folic acid supplementation could
characterize women that planned a pregnancy but did not
become pregnant during the first months, thus including a
subgroup of sub-fertile women [35]. In MoBa, the women
were asked to report the number of months with regular
intercourse without contraception before becoming preg-
nant, and these data were classified as follows: <1 month
(n = 12,912, 20%), 1–2 months (n = 14,818, 23%) and >2
months (n = 21,883, 33%). Stratification for this variable still
showed increased HRs for the early initiation of folic acid
supplementation in the subgroup that became pregnant
within the first month (HR 1.39; CI 1.02-1.89), again with
larger HRs for the subgroup with early PTD (HR 2.32; CI
1.20-4.48).
Pregnancy period of folic acid supplementation and risk
for spontaneous PTD
The time of folic acid supplementation was represented by
four variables corresponding to the following periods: 26–9
weeks before conception, 0–8 weeks before conception,
first trimester and second trimester. If the Cox regression
included all of the confounders and the outcome of spon-
taneous PTD was analyzed, the prediction of the model
improved after introducing all four folic acid supplemen-
tation variables (p = 0.005). Folic acid supplement use
more than 8 weeks pre-conception was associated with an
increased HR for spontaneous PTD, even after adjusting
for the supplementation at all other time points studiedng pregnancy. Prevalence of folic acid and vitamin A
taneous term or preterm delivery (22+0-36+6 weeks, n = 1,628) among
– 2009).
Table 2 Folate intake from diet and supplements
All Spontaneous term delivery Spontaneous PTD1
Folate (μg/d) Median IQR Median IQR Median IQR
All women n = 65668 n = 50301 n = 1628
Diet 155 (123–193) 155 (123–193) 155 (123–194)
Supplements 67 (0–400) 57 (0–400) 100 (0–400)
Total intake 266 (154–543) 262 (153–542) 280 (154–557)
Supplement users n = 35510 n = 27007 n = 891
Diet 158 (127–196) 158 (127–196) 159 (128–197)
Supplements 400 (200–429) 400 (200–429) 400 (200–457)
Total intake 530 (354–636) 530 (354–635) 540 (369–651)
Folic acid supplementation, dietary and total folate intake during the first half of pregnancy (FFQ data) for all 65,668 participants, as well as in folic acid
supplement users (n = 35,510), from the Norwegian Mother and Child Cohort Study (2002–2009).
1Preterm delivery defined as delivery between 22+0-36+6 weeks of gestation.
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creased HRs for first-trimester supplementation was no
longer significant if the model was adjusted for vitamin A
supplementation (data not shown).Discussion
In this large prospective national birth cohort study, we
did not find any statistically significant association between
the amount of folate intake from the diet or supplements
and spontaneous PTD in uncomplicated pregnancies. Folic
acid supplementation starting more than 8 weeks before
conception was associated with an increased HR for spon-
taneous PTD.
When interpreting the results, the selection of the
study population has to be kept in mind: all known
risk-pregnancies due to maternal disease, pregnancy
complications or fetal malformation have been excluded
from the analysis. There might be an association between
the amount of folate intake from diet or supplements and
spontaneous PTD in those pregnancies excluded.Table 3 Folate intake from different sources and risk of
spontaneous preterm delivery (PTD)
Unadjusted Adjusted2
Folate (μg/d) HR1 (CI) p HR1 (CI) p
Diet 1.10 (0.73–1.66) 0.66 1.16 (0.65–2.08) 0.61
Supplements 1.06 (0.97–1.16) 0.17 1.04 (0.95–1.13) 0.43
Total intake 1.06 (0.98–1.15) 0.16 1.04 (0.95–1.14) 0.39
Amount of folic acid supplementation, dietary and total folate intake (FFQ
data) and hazard ratios for spontaneous PTD (22+0-36+6 weeks, n = 1,628). Cox
regression for 65,668 participants in the Norwegian Mother and Child Cohort
Study (2002–2009). Iatrogenic deliveries have been censored in the
regression model.
1 HR per 500 μg extra folate/d.
2 Cox regression, adjusted for maternal age, prepregnancy BMI, parity, history
of PTD and spontaneous abortion, child’s sex, smoking habits and alcohol
consumption during pregnancy, maternal education, marital status, household
income, energy intake. Mutual adjustment for dietary and supplemental
folate intake.Our results, demonstrating no significant protective effect
of the maternal folate intake or folic acid supplementation
on the spontaneous PTD risk, support a number of earlier
observational studies [36-41] and RCTs [6,42,43]. A re-
analysis of the most recent Cochrane review, based on data
from 21 studies and one of the largest RCTs as well as a re-
cent meta-analysis of all RCTs published to date, could not
confirm the effect of the maternal folate status on the gesta-
tional length or risk of PTD [23,24]. Shaw et al. found a
comparable association of increased PTD risk and pre-
conceptional folic acid supplementation when analyzing
data from the US National Birth Defects Study [41]. In
addition, extensive supplementation with multivitamins with
a major folic acid component was associated with an in-
creased risk of PTD in a study by Alwan et al. [36].
However, some recent observational studies have found
that folic acid supplementation reduces the risk of PTD
[20-22]. In some cases, this association was linked to pre-
conceptional folic acid supplementation for 1 year or lon-
ger [21] or third-trimester folic acid supplementation [22],
raising questions about extended supplementation schemes
compared to the NTD prevention scheme. A protective ef-
fect of folic acid supplementation was supported by a mod-
est reduction in the PTD rate after the introduction of
folate fortification of foods [9].
One of the most obvious explanations for these conflicting
results could be the dosage of folic acid. While most of the
studies finding an association with gestational length or
PTD were based on comparably high doses of folic acid
(≥5000 μg/d [20,22,44], ≥2500 μg/d [22,45] and ≥500
μg/d [46-48]), very few women in our study population
consumed as much as 5000 μg/d of supplemental folic
acid, while only 9% consumed >500 μg/d and 15% con-
sumed >400 μg/d. However, the Hungarian RCT, one of
the biggest performed so far, did not find any effect of a
high dosage of 8000 μg/d of folic acid supplementation
on PTD [6]. Unfortunately, the folic acid dosage was
not indicated in all of the studies [21,35].
Table 4 Initiation of pre-conceptional folic acid supplementation and risk of spontaneous preterm delivery (sPTD)
sPTD Initiation of folic acid Unadjusted Adjusted1 Adjusted2
supplementation n HR (CI) p HR (CI) p HR (CI) p
No 919 1 1 1
All 0-8 w preconceptional 281 0.94 (0.82–1.07) 0.36 1.01 (0.88–1.16) 0.91 1.02 (0.88–1.17) 0.82
>8 w preconceptional 428 1.14 (1.02–1.28) 0.02 1.19 (1.05–1.34) 0.01 1.19 (1.04–1.35) 0.01
No 139 1 1 1
Early 0-8 w preconceptional 46 1.02 (0.73–1.42) 0.92 1.15 (0.82–1.62) 0.43 1.10 (0.77–1.57) 0.59
>8 w preconceptional 79 1.39 (1.06–1.84) 0.02 1.53 (1.14–2.04) 0.004 1.45 (1.05–1.99) 0.02
No 780 1 1 1
Late 0-8 w preconceptional 235 0.93 (0.8–1.07) 0.30 0.98 (0.85–1.14) 0.83 1.00 (0.86–1.17) 0.98
>8 w preconceptional 349 1.10 (0.97–1.25) 0.14 1.13 (0.99–1.29) 0.07 1.14 (0.99–1.32) 0.07
Initiation of pre-conceptional folic acid supplementation (Q1 data) and hazard ratios for spontaneous PTD (n = 1,628 for 22+0-36+6 weeks, n = 264 for early (22+0-33
+6 weeks), n = 1,364 for late (34+0-36+6 weeks)). Cox regression for 65,668 participants in the Norwegian Mother and Child Cohort Study (2002 – 2009). Iatrogenic
deliveries have been censored in the regression model.
1 Cox regression, adjusted for maternal age, prepregnancy BMI, parity, history of PTD and spontaneous abortion, child’s sex, smoking habits and alcohol
consumption during pregnancy, maternal education, marital status, household income, energy intake and dietary folate intake.
2 Adjustment as above as well as for first-trimester folic acid supplementation and pre-conceptional and first-trimester vitamin A supplementation.
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alone or when studying populations with different dietary
folate intakes are additional factors compromising com-
parability and generalizability between studies. While re-
cent US studies are performed against the background of
mandatory folate fortification of food [21,41], other studies
have examined supplementation effects in folate-deficient
populations [44]. Few studies have assessed the effects of
both dietary folate and folic acid supplementation separ-
ately [41] or combined [20,47,49], and adjustments for bio-
availability are rare. In this Norwegian study population,
only 0.4% of the participants reached the Nordic NutritionTable 5 Timing of folic acid supplementation and risk of spon
sPTD Time of olic acid U
supplementation n HR
>8 w pre-conceptional 428 1.16
All 0-8 w pre-conceptional 572 1.02
1st trimester 1185 0.94
2nd trimester 795 1.11
>8 w pre-conceptional 79 1.39
Early 0-8 w pre-conceptional 103 1.21
1st trimester 199 1.07
2nd trimester 137 1.26
>8 w pre-conceptional 349 1.12
Late 0-8 w pre-conceptional 469 0.99
1st trimester 986 0.91
2nd trimester 658 1.09
Folic acid supplementation at different times (Q1 and Q3 data) and hazard ratios fo
n = 1,364 for late (34+0-36+6)). Cox regression for 65,668 participants in the Norwegi
been censored in the regression model.
1 Cox regression, adjusted for maternal age, prepregnancy BMI, parity, history of PT
consumption during pregnancy, maternal education, marital status, household inco
supplementation at other time points.Recommendation of 500 μg/d with their dietary folate in-
take (adjusted with a factor of 0.6 for bioavailability; 2.8%
without adjustment), and 31% of the participants achieved
the recommended level with their total folate intake (39.6%
without adjustment). After stratification for dietary folate in-
take, the early initiation of folic acid supplementation was
significantly associated with spontaneous PTD in the sub-
group of women with low but not high dietary folate intakes.
There were no significant associations between high total
folate intakes and PTD risk in the MoBa study population.
Confounding is always an issue when assessing the ef-
fect of a single environmental factor on a complextaneous preterm delivery (sPTD)
nadjusted Adjusted1
(CI) p HR (CI) p
(1.04–1.30) 0.01 1.16 (1.02–1.31) 0.02
(0.93–1.13) 0.64 1.04 (0.92–1.17) 0.52
(0.84–1.05) 0.25 0.88 (0.78–0.99) 0.04
(1.01–1.23) 0.03 1.10 (0.99–1.21) 0.08
(1.07–1.80) 0.01 1.34 (0.99–1.80) 0.06
(0.94–1.55) 0.13 1.18 (0.88–1.58) 0.26
(0.81–1.42) 0.62 0.94 (0.69–1.28) 0.67
(0.99–1.60) 0.06 1.18 (0.91–1.51) 0.21
(0.99–1.27) 0.07 1.13 (0.98–1.29) 0.09
(0.89–1.11) 0.88 1.01 (0.89–1.15) 0.84
(0.81–1.03) 0.14 0.87 (0.76–0.99) 0.04
(0.98–1.21) 0.13 1.08 (0.97–1.21) 0.17
r spontaneous PTD (n = 1,628 for 22+0-36+6 weeks, n = 264 for early (22+0-33+6),
an Mother and Child Cohort Study (2002 – 2009). Iatrogenic deliveries have
D and spontaneous abortion, child’s sex, smoking habits and alcohol
me, energy intake and dietary folate intake. Mutual adjustment for folic acid
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http://www.biomedcentral.com/1471-2393/13/160outcome like PTD. For example, it is well established that
women with high levels of education, privileged socioeco-
nomic status and healthier overall diets are more likely to
use supplements during pregnancy [50,51] and less likely
to experience PTD than women without these characteris-
tics. Some observational studies failed to adjust for these
confounders, and the effect attributed to folic acid supple-
mentation might in fact be confounded by overall health
and lifestyle behaviors. While the strength of the signifi-
cance was moderate, the association with the early onset of
folic acid supplementation in the current study remained
significant even after extensive adjustment for maternal
characteristics such as socioeconomic and life-style param-
eters as well as obstetric anamnesis.
Associations with the early start of supplementation
should be studied with particular caution. The early
start of folic acid supplementation might partially iden-
tify a group of women with a history of adverse preg-
nancy outcomes who want to optimize conditions for
their current pregnancy. As presented in Table 1, women
who had previously experienced spontaneous abortions
were more likely to initiate folic acid supplementation early
in their subsequent pregnancies. However, the same associ-
ation of the early initiation of folic acid supplementation and
spontaneous PTD was found in primi-gravidae. Folic acid
supplementation starting more than 8 weeks prior to con-
ception might characterize women who planned a preg-
nancy but did not become pregnant during their first 2
cycles, thus constituting a subgroup of women with subopti-
mal fertility [35]. The same association of the early start of
supplementation was found in the group of women that be-
came pregnant within the first month. Women who choose
to start early with folic acid supplementation might be dis-
tinguished by some other characteristic that could be the
causal link to spontaneous preterm delivery so that we can-
not exclude confounding.
In addition to the amount of folic acid, the composition
of supplements is another point of discussion. In some
countries like Greece and Norway, commonly used sup-
plements contain folic acid and/or iron only [20]. In other
countries, folic acid is mainly consumed in the form of
multivitamins, making it difficult to differentiate the ef-
fects of multivitamin use and folic acid supplementation
[21,35,41,48]. Vitamins other than folic acid might ex-
plain the association between multivitamin use and
PTD. Catov et al. found that in the Danish birth cohort,
multivitamin use was associated with modestly de-
creased PTD rates, while there was no association with
folic acid supplementation [37]. As seen from Figure 1,
vitamin A consumption (as a proxy for multivitamin
supplementation) differed considerably from folic acid
supplementation. However, the MoBa FFQ allowed us
to calculate folic acid separately from other supple-
ments, and adjusting for vitamin A consumption didnot change the results for pre-conceptional folic acid
supplementation.
Apart from the amount, timing and composition of folate
exposure, differences in the definition of pregnancy out-
comes hinder comparability. Most studies defined PTD as
delivery at <37+0 weeks of gestation without indicating the
range of gestational age. This information might be import-
ant, especially if the risk of early PTD is found to be associ-
ated with folate status, as suggested by this study and that
of Bukowski et al. [21]. Although PTD is a heterogeneous
pregnancy outcome with distinct etiologies for different
subgroups [25], not all studies analyzed clearly defined sub-
groups such as spontaneous PTD [20,21,37,40,47,52].
Strengths and weaknesses
With a sample size of 65,668 pregnancies, this was a well-
powered study for investigating the association of folate
intake and pregnancy outcomes. Due to the large study
sample, there were 1,628 cases defined as spontaneous
PTD and 264 and 1,364 cases in the subgroups of early
and late spontaneous PTD, respectively. The estimation of
the gestational length by the second-trimester ultrasounds
and the definition of a clear spontaneous PTD phenotype
distinguishes this study [25].
The MoBa participation rate is 38.5%, and a demo-
graphic comparison with the MBRN in 2002 showed that
single women and women <25 y of age are underrepre-
sented in MoBa. Regarding PTD (7.2% in MoBa and 7.7%
in MBRN), the differences are minor, and even the sub-
group composition is similar to the distribution in the total
population, with spontaneous PTD accounting for 42% of
all PTD [15]. Additionally, a recent study found no bias in
8 selected exposure-outcome associations [53].
The assessment of folate from both the diet and supple-
ments is a clear strength of this study. Although all dietary
assessment methods have limitations, the MoBa FFQ has
been extensively validated in a sub-population of 119 MoBa
participants using a 4-day weighed food diary and biological
markers in the blood and urine as reference measures [54].
The dietary supplement use was evaluated specifically. The
total folate intake by the FFQ showed good agreement
with the folate intake detailed by the food diary and was
significantly reflected by the serum folate concentra-
tions [31]. In a subsample of an earlier MoBa version
(2934 singleton pregnancies), Nilsen et al. did not find
any significant associations of dietary folate intake, folic acid
supplementation or plasma folate with PTD. This study
also reported good agreement between the folate intake
(dietary and supplements) by the MoBa FFQ and plasma
folate concentration (r = 0.44, CI: 0.41-0.47) [38]. As the
relevant window of susceptibility for folate effects regard-
ing pregnancy outcomes other than NTD is not yet known,
the assessment of folate intake at different time points is a
further strength of this study. The prospective design
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http://www.biomedcentral.com/1471-2393/13/160ensured that the women’s answers were not influenced by
their knowledge of pregnancy outcomes.Conclusions
The amount of dietary folate and supplemental folic acid
intake in uncomplicated 65,668 singleton pregnancies
from the Norwegian Mother and Child Cohort Study was
not associated with a risk of spontaneous PTD, at least
not at the relatively low intake levels of dietary folate (me-
dian 155 μg/d corrected for bio-availability, uncorrected
258 μg/d) and supplemental folic acid (median 400 μg/d)
in this healthy study population.
The initiation of folic acid supplementation more than 8
weeks prior to conception was associated with an in-
creased risk for overall and early spontaneous PTD in
both the overall analyses and in the strata of women with
low dietary folate intake.
Even if MoBa allows adjustment for a variety of con-
founders, the presence of residual confounding cannot be
ruled out. However, our results require careful investiga-
tion regarding dosage and timing of folic acid supplemen-
tation, such as in the form of an RCT, before discussing a
change of the current guidelines.Additional files
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